Oyster Point Pharma, Inc. (OYST) Financial Analysis & Valuation | Quarter Chart
Oyster Point Pharma, Inc. (OYST)
OYSTPrice: $11.17
Fair Value: 🔒
🔒score
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The compa... more
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, I... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jeffrey Nau |
| IPO Date | 2019-10-31 | CAGR | — |
| Employees | 303 | Website | www.oysterpointrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
OYST chart loading...
Fundamentals
Technicals
| Enterprise Value | $176.71M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.92 |
| P/CF Ratio | -3.25 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 9.15% | Gross Margin | 0.94% |
| Operating Margin | -3.95% | Profit Margin | -4.25% |
| ROE | -0.73% | ROA | -0.47% |
| ROCE | -0.5% | Current Ratio | 7.47 |
| Quick Ratio | 7.26 | Cash Ratio | 6.71 |
| Debt/Equity | 0.93 | Interest Coverage | -25.96 |
| Altman Z Score | — | Piotroski Score | — |